Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegzilarginase and Pembrolizumab in Extensive Disease Small Cell Lung Cancer
NCT03371979Phase 2Terminated
- Sponsor
- Immedica
- Start
- Dec 2017
- Primary completion
- Jun 2020
- Modality
- PEGylated Peptides, Replacement Enzymes
- Countries
- 2
01
Overview
A Phase 2 trial of pegzilarginase in small cell lung cancer (SCLC), sponsored by Immedica. Started Dec 2017; status: terminated.
02
Drugs
pegzilarginase
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03371979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03371979.